EGFR and colorectal cancer: In colorectal cancer patients receiving anti‐EGFR monoclonal antibody therapy, RAS and EGFR‐extracellular domain mutations were detected in ctDNA 10 months before radiographic progression, and these mutations disappeared after discontinuation of anti‐EGFR therapy.397, 398